Last edition
News about
Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma
Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
SwishX Launches World's First Agentic AI Platform for Pharma and Medtech
SwishX launches the world’s first agentic AI platform for pharma and medtech, targeting rapid global expansion and USD 5 million ARR with 100+ enterprise clients across emerging markets.
Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954
Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.
Scientists at The University of Tulsa have developed new memantine-based compounds capable of crossing the blood-brain barrier and demonstrating higher anticancer activity against glioblastoma cells than standard chemotherapy treatments.
Hengrui Pharma and Braveheart Bio have reported positive Phase 2 clinical trial results for investigational cardiac therapy HRS/BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, demonstrating improvements in cardiac function, biomarkers and patient outcomes.
HealthQuad Invests in AI-Based Remote Patient Monitoring Firm LifeSigns
HealthQuad has invested in LifeSigns to support the expansion of its AI-powered remote patient monitoring platform, aiming to advance predictive healthcare and scale operations across India and international markets.
Partner Therapeutics Wins FDA Approval for BIZENGRI in NRG1+ Cholangiocarcinoma
Partner Therapeutics receives US Food and Drug Administration (FDA) approval for BIZENGRI, the first targeted therapy for NRG1 fusion-positive cholangiocarcinoma, expanding use across NSCLC and pancreatic cancer.
GSK Partners with Sino Biopharmaceutical to Accelerate Hepatitis B Therapy Launch in China
GSK and Sino Biopharmaceutical’s CTTQ have partnered to accelerate the launch of bepirovirsen in China, aiming to expand access to a potential first-in-class chronic hepatitis B therapy with functional cure potential.
Daiichi Sankyo Unveils 5-Year Oncology Growth Strategy
Daiichi Sankyo launches a 5-year strategy targeting global oncology leadership, aiming for 2.3 trillion yen in oncology revenue by 2030 through new indications, breakthrough technologies, and expanded commercialisation capabilities.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy